| | BOSTON and ATLANTA, April 6, 2022 /PRNewswire/ -- Inhibikase Therapeutics Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced that it will host a virtual KOL investor event on Wednesday, April 20, 2022 at 10:00 am ET. 
The virtual event will feature presentations and an interactive Q&A session from the Company’s executive leadership team as well as key opinion leaders, Dr. Robert F. Hauser, Director of Parkinson’s & Movement Disorder Center and Professor, College of Medicine Neurology at University of South Florida and Dr. Werner Poewe, Professor of Neurology and Director of the Department of Neurology at Innsbruck Medical University in Innsbruck, Austria. Presentations will highlight recently presented Phase 1 and Phase 1b data for the Company’s lead candidate, IkT-148009 for the treatment of Parkinson’s disease, provide an overview of the upcoming Phase 2 program, and highlight the current unmet need and competitive landscape in Parkinson’s disease. A live webcast of the Company’s event will be available on the “News & Events” in the Investors section of the Company’s website at www.inhibikase.com. A replay of the webcast will be available for 90 days following the presentation. About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent Imatinib that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company’s RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts. Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD. Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase’s filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2021, including under the caption “Risk Factors.” Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contacts:
Company Contact:
Milton H. Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-host-virtual-kol-investor-event-on-april-20-2022-301517229.html
SOURCE Inhibikase Therapeutics, Inc. | |
